Pfizer Q1 2025 revenue drops 8% to $13.7 billion
Delivers robust earnings performance, successfully navigating a dynamic environment
Delivers robust earnings performance, successfully navigating a dynamic environment
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Bayer expects 2025 to be the most difficult year of its turnaround
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
A new weapon in the global fight against malaria
SmartTrack aims to reduce the need for clinical studies in generic drug product approvals
Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed
Aarti Pharmalabs becomes 6th Indian Pharma/CDMO to earn SBTi approval for all 3 Scopes since 2022 demerger
Subscribe To Our Newsletter & Stay Updated